| Training Population N = 417 | Testing Population N = 164 | ||
---|---|---|---|---|
 | Exac. | Non-exac. | Exac. | Non-exac. |
Subjects | 127 (30%) | 290 (70%) | 50 (30%) | 114 (70%) |
Age (mean ± s.d.) | 8.41 ± 2.07 | 8.89 ± 2.07 | 8.54 ± 2.28 | 9.45 ± 2.19 |
Male | 69% | 61% | 46% | 53% |
FEV1% (mean ± s.d.) | 92.9 ± 15.7 | 93.5 ± 13.2 | 95.4 ± 17.1 | 95.4 ± 13.5 |
Treatment | Â | Â | Â | Â |
   Budesonide | 20% | 31% | 36% | 32% |
   Nedocromil | 28% | 29% | 30% | 32% |
   Placebo | 52% | 39% | 34% | 36% |